{"title":"多发性骨髓瘤的治疗:Quo Vadis?","authors":"L. Rasche, K. M. Kortuem, H. Einsele","doi":"10.17925/EOH.2015.11.02.107","DOIUrl":null,"url":null,"abstract":"Two major developments are changing our current understanding of cancer: (1) the in-depth analysis of tumour-harbouring mutations and (2) the generation of highly active T cell-involving immunotherapies. In this editorial, we focus on its impact on myeloma therapy and speculate on future treatment concepts.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"21 1","pages":"107"},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Therapy for Multiple Myeloma - Quo Vadis?\",\"authors\":\"L. Rasche, K. M. Kortuem, H. Einsele\",\"doi\":\"10.17925/EOH.2015.11.02.107\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Two major developments are changing our current understanding of cancer: (1) the in-depth analysis of tumour-harbouring mutations and (2) the generation of highly active T cell-involving immunotherapies. In this editorial, we focus on its impact on myeloma therapy and speculate on future treatment concepts.\",\"PeriodicalId\":38554,\"journal\":{\"name\":\"European Oncology and Haematology\",\"volume\":\"21 1\",\"pages\":\"107\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Oncology and Haematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17925/EOH.2015.11.02.107\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Oncology and Haematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/EOH.2015.11.02.107","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Two major developments are changing our current understanding of cancer: (1) the in-depth analysis of tumour-harbouring mutations and (2) the generation of highly active T cell-involving immunotherapies. In this editorial, we focus on its impact on myeloma therapy and speculate on future treatment concepts.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
